This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ANCN Anchiano Therapeutics (ANCN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Anchiano Therapeutics Stock (NASDAQ:ANCN) Get Anchiano Therapeutics alerts:Sign Up Key Stats Today's Range$1.66▼$1.7750-Day Range$2.82▼$59.0052-Week Range$0.51▼$10.55Volume30,960 shsAverage Volume3.15 million shsMarket Capitalization$12.69 millionP/E Ratio11.40Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts. Read More Receive ANCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anchiano Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANCN Stock News HeadlinesRakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture FinancingMay 29, 2023 | finance.yahoo.comITeos Therapeutics Inc Ordinary SharesMay 27, 2023 | morningstar.comMHave $300? Do this to get ahead of Elon Musk’s $119 billion planElon Musk is putting a $119 billion plan in motion across Tesla, SpaceX, and xAI. Larry Benedict, who ran a $900 million hedge fund and posted 20 straight years without a losing year, says one forgotten American company has suddenly become critical to that plan. Wall Street is still judging the stock by its past. Benedict is focused on what Musk may need from it next, and he says the gap between the two is the opportunity.November 1 at 1:00 AM | Brownstone Research (Ad)ENDV Endonovo Therapeutics, Inc.May 20, 2023 | seekingalpha.comLooking Into Oncternal Therapeutics's Return On Capital EmployedMay 18, 2023 | msn.comAnticompetitive Behavior At United Therapeutics, Regeneron, And The FTCMay 18, 2023 | msn.comFTC sues to block Amgen’s acquisition of Horizon TherapeuticsMay 16, 2023 | msn.comFTC sues to block Amgen acquisition of Horizon TherapeuticsMay 16, 2023 | msn.comSee More Headlines ANCN Stock Analysis - Frequently Asked Questions How were Anchiano Therapeutics' earnings last quarter? Anchiano Therapeutics Ltd. (NASDAQ:ANCN) released its earnings results on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.12. When did Anchiano Therapeutics IPO? Anchiano Therapeutics (ANCN) raised $35 million in an initial public offering (IPO) on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager. What other stocks do shareholders of Anchiano Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anchiano Therapeutics investors own include Agenus (AGEN), Bio-Path (BPTH), Inovio Pharmaceuticals (INO), NIO (NIO), Arbutus Biopharma (ABUS), Aurora Cannabis (ACB) and Achieve Life Sciences (ACHV). Company Calendar Last Earnings8/05/2019Today11/01/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ANCN CIKN/A Webwww.anchiano.com Phone857-259-4622FaxN/AEmployees16Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.46) Trailing P/E Ratio11.40 Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.12 million Net MarginsN/A Pretax MarginN/A Return on Equity36.08% Return on Assets27.40% Debt Debt-to-Equity RatioN/A Current Ratio3.25 Quick Ratio3.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book0.85Miscellaneous Outstanding Shares7,420,000Free FloatN/AMarket Cap$12.69 million OptionableNot Optionable Beta0.93 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:ANCN) was last updated on 4/8/2026 by MarketBeat.com Staff. From Our PartnersThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
